Niagen Bioscience
NAGE
54 hedge funds and large institutions have $16.4M invested in Niagen Bioscience in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 17 reducing their positions, and 5 closing their positions.
416% more call options, than puts
Call options by funds: $98K | Put options by funds: $19K
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.07% less ownership
Funds ownership: 15.02% → 14.95% (-0.07%)
2% less funds holding
Funds holding: 55 → 54 (-1)
7% less capital invested
Capital invested by funds: $17.7M → $16.4M (-$1.3M)
59% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$217K |
| 2 |
CCM
Cox Capital Management
Andover,
Massachusetts
|
+$145K |
| 3 |
GI
GAMCO Investors
Greenwich,
Connecticut
|
+$85.1K |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$71.3K |
| 5 |
Squarepoint
New York
|
+$30K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tieton Capital Management
Yakima,
Washington
|
-$185K |
| 2 |
Millennium Management
New York
|
-$78.7K |
| 3 |
D.E. Shaw & Co
New York
|
-$59.2K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$45.1K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$39.7K |
NAGE Hedge Fund Activity: Q3 2023 in Review
54 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q3 2023, worth a combined $16.4M — down 7.3% from $17.7M a quarter earlier.
Fund positioning in NAGE was balanced in Q3 2023: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 17 trimmed.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $217K. The largest seller was Tieton Capital Management, cutting an estimated $185K.
- 54 institutional investors held Niagen Bioscience (NAGE) as of Q3 2023, down from 55 in Q2 2023.
- Funds reported $16.4M of Niagen Bioscience stock for Q3 2023, down 7.3% quarter-over-quarter.
- 5 funds opened new Niagen Bioscience positions in Q3 2023 and 5 closed out, a net change of 0 holders.
- The largest Niagen Bioscience buyer in Q3 2023 was Boothbay Fund Management, an estimated $217K added.
- The largest Niagen Bioscience seller in Q3 2023 was Tieton Capital Management, an estimated $185K sold.
Based on aggregated 13F filings for Q3 2023.